Unicycive Therapeutics (UNCY) Q2 2024 earnings summary

Executive summary

• Net loss for the six months ended June 30, 2024 was $11.1 million, a 40% improvement from the $18.4 million loss in the prior year period, driven by a significant increase in other income from warrant liability revaluation.

• Achieved positive topline results from the pivotal OLC clinical trial, confirming safety and tolerability in CKD patients on dialysis.

• NDA submission for OLC on track for end of August 2024; all FDA requirements from the pivotal trial believed to be met.

• Completed enrollment in UNI-494 Phase 1 study targeting acute kidney injury; results expected in Q3 2024.

• A $50 million private placement of Series B Convertible Preferred Stock was completed in March 2024, strengthening liquidity.

Financial highlights

• Research and development expenses increased 121% year-over-year to $11.7 million for the six months ended June 30, 2024.

• General and administrative expenses rose 26% to $4.9 million for the same period.

• Other income swung to $5.5 million from a $9.9 million expense, primarily due to a $15.1 million positive change in fair value of warrant liability.

• Net income attributable to common stockholders was $3.0M for Q2 2024, compared to a net loss of $4.4M in Q2 2023.

• Cash and cash equivalents increased to $41.8 million as of June 30, 2024, up from $9.7 million at December 31, 2023.

Outlook and guidance

• NDA submission for OLC expected by end of August 2024; high confidence in commercial potential if approved.

• UNI-494 Phase 1 results anticipated in Q3 2024.

• Sufficient resources are available to fund operations for at least one year, with current cash position expected to support planned operations into 2026.